# Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas

> **NCT00553189** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 31 (actual)

## Conditions studied

- Solid Tumors
- Lymphomas

## Interventions

- **DRUG:** ABT-888
- **DRUG:** Topotecan

## Key facts

- **NCT ID:** NCT00553189
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08-09
- **Primary completion:** 2008-02-01
- **Final completion:** 2011-09-28
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00553189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00553189, "Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00553189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*